High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
about
Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation.Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemiaNew considerations in the design of clinical trials for the treatment of acute leukemia.Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.What happened to anti-CD33 therapy for acute myeloid leukemia?Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.Gemtuzumab ozogamicin in acute myeloid leukemia revisited.Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia.Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study.
P2860
Q33412354-569608E2-8F06-4B61-A1E9-50C7C64E6B79Q33418153-6CA1BE8F-3A31-479D-851D-4A50986F5EF3Q34314177-5755046C-AD71-46E3-B62D-898DE6A21CA9Q36641721-6634047F-8D6E-407D-A492-FDD6773DC426Q37910260-5B33913A-4E3C-464C-B197-C89A194814C7Q37959880-C5B195E7-2082-494C-B817-BD753C2B5F72Q38109541-4894243D-9F85-4EB5-89FD-0D24A30920E8Q38215269-28CBE528-4C23-4DCF-8D3B-5A29EBE1549CQ39067366-7E5B0E2D-B485-4931-9FC1-34D0D907C4F6Q40872029-3F512B93-6AEF-48E6-95CF-D434DAA45100Q44462005-FDA8374D-9260-4DDD-9C16-9C64F4F24B7BQ47730914-F94423ED-98A1-4E65-A6EC-EA2A88D43BCEQ50512245-9FE60164-75B5-4AB3-81F3-D071A7819C1DQ50913503-5307BDC7-E096-4A52-A607-181602401A61
P2860
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
High dose cytarabine plus gemt ...... Leukemia Group B study 19902.
@ast
High dose cytarabine plus gemt ...... Leukemia Group B study 19902.
@en
High dose cytarabine plus gemt ...... Leukemia Group B study 19902.
@nl
type
label
High dose cytarabine plus gemt ...... Leukemia Group B study 19902.
@ast
High dose cytarabine plus gemt ...... Leukemia Group B study 19902.
@en
High dose cytarabine plus gemt ...... Leukemia Group B study 19902.
@nl
prefLabel
High dose cytarabine plus gemt ...... Leukemia Group B study 19902.
@ast
High dose cytarabine plus gemt ...... Leukemia Group B study 19902.
@en
High dose cytarabine plus gemt ...... Leukemia Group B study 19902.
@nl
P2093
P2860
P1433
P1476
High dose cytarabine plus gemt ...... Leukemia Group B study 19902.
@en
P2093
Barry Moser
Ben Sanford
David Hurd
Ilene Galinsky
Jonathan E Kolitz
Philip Schulman
Richard A Larson
Richard M Stone
Steven Allen
P2860
P304
P356
10.1016/J.LEUKRES.2010.07.017
P577
2010-08-04T00:00:00Z